AFLIMAB Trademark

Trademark Overview

On Monday, December 9, 2019, a trademark application was filed for AFLIMAB with the United States Patent and Trademark Office. The USPTO has given the AFLIMAB trademark a serial number of 79276761. The federal status of this trademark filing is REGISTERED as of Tuesday, January 5, 2021. This trademark is owned by Klinge Biopharma GmbH. The AFLIMAB trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of angiogenesis and ocular diseases and disorders; biologic medicines for the treatment of angiogenesis and ocular diseases and disorders
aflimab

General Information

Serial Number79276761
Word MarkAFLIMAB
Filing DateMonday, December 9, 2019
Status700 - REGISTERED
Status DateTuesday, January 5, 2021
Registration Number6235846
Registration DateTuesday, January 5, 2021
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 20, 2020

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of angiogenesis and ocular diseases and disorders; biologic medicines for the treatment of angiogenesis and ocular diseases and disorders

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, January 27, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameKlinge Biopharma GmbH
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressDE
Party NameKlinge Biopharma GmbH
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressDE
Party NameKlinge Biopharma GmbH
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressDE

Trademark Events

Event DateEvent Description
Monday, March 9, 2020ASSIGNED TO EXAMINER
Wednesday, March 11, 2020NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Thursday, March 26, 2020REFUSAL PROCESSED BY MPU
Thursday, January 23, 2020SN ASSIGNED FOR SECT 66A APPL FROM IB
Monday, January 27, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, January 31, 2020APPLICATION FILING RECEIPT MAILED
Tuesday, March 10, 2020NON-FINAL ACTION WRITTEN
Thursday, September 10, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, September 10, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, September 10, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, September 10, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, September 10, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, September 11, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, March 26, 2020NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, April 10, 2020REFUSAL PROCESSED BY IB
Thursday, September 10, 2020TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Friday, September 11, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Saturday, September 12, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, September 30, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, September 30, 2020NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Sunday, September 13, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, September 30, 2020NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Sunday, October 18, 2020NOTIFICATION PROCESSED BY IB
Tuesday, October 20, 2020PUBLISHED FOR OPPOSITION
Tuesday, October 20, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 5, 2021REGISTERED-PRINCIPAL REGISTER
Monday, April 5, 2021FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Sunday, May 2, 2021FINAL DECISION TRANSACTION PROCESSED BY IB
Friday, April 1, 2022NEW REPRESENTATIVE AT IB RECEIVED
Sunday, May 26, 2024NEW REPRESENTATIVE AT IB RECEIVED
Friday, June 4, 2021NEW REPRESENTATIVE AT IB RECEIVED
Thursday, April 8, 2021FINAL DISPOSITION PROCESSED
Thursday, April 8, 2021FINAL DISPOSITION NOTICE SENT TO IB

Related Keywords

aflimab diseases disorders angiogenesis ocular treatment medicines biologic preparations pharmaceutical